AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04824053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conventional yogurt
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months
Study NCT04824053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months
Study NCT04824053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conventional fresh cheese
Description: The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months
Study NCT06486207 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gong's mobilization
Description: increases the range of motion for shoulder medial rotation by allowing shoulder medial rotation with the humeral head in a normal position against the glenoid cavity of the scapula
Study NCT06486207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kendall Exercise
Description: The Kendall exercise methods were as follows: Strengthening the deep cervical flexors, lying flat on the back with the chin down and then lifting the head and holding this position for 2-8 seconds to strengthen deep cervical flexors
Study NCT05500443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (Menaquinone-7)
Description: Oral supplementation with vitamin K2 (Menaquinone-7 (MK-7)) 720 µg/day and D 25 µg/day
Study NCT05500443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin K2 (Menaquinone-7)
Description: Oral supplementation with vitamin K2 (Menaquinone-7 (MK-7)) 720 µg/day and D 25 µg/day
Study NCT05066737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral suspension via V-NOTES surgery
Description: pop-q, pisq-12 assesment of patients with pelvic organ prolapse before and 6 or 12 month after lateral suspension surgery performed via V-NOTES technique.
Study NCT05877313 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water foot bath
Description: Participants will use the same foot bath and sterile water used in the treatment arm minus the active ingredients.
Study NCT05877313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Participants will use a foot bath filled with 500mL of NORS for 15 min. The solution's two components are mixed 1:1 to 500mL in the foot bath immediately before treatment. The solution contains NO at 68.9ppm\*hrs and 203.2ppm\*hrs for 1X and 2X solutions respectively, and it acts as a virucidal agent. Instructions for storage, handling, and use will be provided to site staff and participants.
Study NCT05609201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HRCT Thorax
Description: HRCT Thorax at 0, 6 and 12 months
Study NCT05609201 — intervention group
Intervention type: DEVICE
Intervention: Glycocheck Endothelial Glycocalyx Assessment
Description: Measure of EG degradation using GlycoCheck Microvascular Health Score at 0, 6 and 12 months
Study NCT05609201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood biomarkers
Description: Endothelial glycocalyx degradation blood biomarkers and angiogenesis markers at 0, 6 and 12 months
Study NCT05609201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral leucocyte telomere length
Description: HT-STELA (High-throughput single telomere length assessment) at 0, 6 and 12 months
Study NCT05609201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function testing
Description: Pulmonary Function Tests (Spirometry and Gas Transfer) and 6-minute walk distance at 0, 6 and 12 months
Study NCT05609201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Patient reported outcome measures
Description: Electronic collection of patient reported outcome measures
Study NCT05229731 — intervention group
Intervention type: PROCEDURE
Intervention: Neurovisual evaluation
Description: Standardized tests and scales classically used during a neurovisual evaluation,
Study NCT05229731 — intervention group
Intervention type: PROCEDURE
Intervention: Cerebral MRI
Description: Sequences realized :~* 3D T1 TFE i1.0~* 3D FLAIR i1.0~* 2D T2 0.3 coro, centré sur les orbites~* 3D T2 i0.6~* SWIp 0.6~* 3D PD T2 NO, centré sur les orbites~* 3D ASL~* DTI 64dir
Study NCT05493241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Independence in Older Veterans (ACTIVaTE)
Description: 6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.
Study NCT05493241 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Activation for Independence in Older Veterans (ACTIVaTE)
Description: 6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.
Study NCT05493241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: An attention control (AC) group will be used to control for the social interaction and educational aspects of ACTIVaTE. The AC arm will consist of 6 weekly one-hour VVC-delivered sessions including friendly social conversation plus education on remaining active within the physical, cognitive, and social domains during older adulthood. During each session, the interventionist will review a relevant handout or other educational materials with the participant. AC interventionists will not be trained in the ACTIVaTE intervention, and the investigators will assess whether any key features of ACTIVaTE (activity monitoring/planning, values exploration, problem-solving) are incidentally incorporated into this arm during fidelity assessment.
Study NCT05344729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 Capsule
Description: It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
Study NCT05444049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEURESCUE device
Description: The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
Study NCT06608173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: radKIDS2.0 Safety and Empowerment Education Program
Description: radKIDS® uses activity-based skill training to help elementary aged children develop personal safety boundaries, critical thinking skills for responding to threats of danger, age-appropriate coping strategies for dealing with current and past victimization, self-assertiveness and physical skills for self-defense, communication skills for reporting incidences to parents/adults, and increasing child self-worth-the program's cornerstone for personal safety and healthy development for elementary students.
Study NCT05396677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 2 x 500 mg acetaminophen (one time)
Study NCT05396677 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 500 mg microcrystalline cellulose (one time)
Study NCT05134441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838 tablets
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1
Study NCT05134441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching IMU-838 tablets
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1
Study NCT05441709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ci-BPC with Standard of Care (SOC)
Description: Clinically-integrated breastfeeding peer counseling (ci-BPC) is a practice that, supports the patient and the clinical care team by delivering culturally-appropriate breastfeeding help to motivate breastfeeding initiation, intensity, and duration, inspiring confidence for patients to set breastfeeding goals and meet them. ci-BPC is delivered by community health workers who have breastfed an infant, and have received basic training in breastfeeding support through a qualified BPC training organization. For this project, the Peer Counselor will make initial contact to patients randomized into the treatment arm via phone to schedule the Intake Encounter between 20 and 30 weeks gestation. Subsequently, each patient will receive a minimum of 3 additional encounters which can occur virtually or in-person. Patients randomized to the ci-BPC arm are additionally offered access to a warmline where messages will be returned by the next business day.
Study NCT04729998 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban film-coated tablet 20 mg
Description: Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.
Study NCT04729998 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Xarelto® film-coated tablet 20 mg
Description: Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.
Study NCT06337526 — intervention group
Intervention type: DEVICE
Intervention: Apple Watch v8
Description: Apple Watch used for data collection only
Study NCT04970030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ML lithotripsy
Description: we will proceed under fluoroscopic vision with TTS mechanical lithotripter (Trapezoid, RX Wireguided Retrieval Basket, Boston Scientific) with mechanical fragmentation of the stone and subsequent complete cleaning of the biliary tract using the fluoroscopic technique.
Study NCT04970030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EHL lithotripsy
Description: after administration of IV antibiotic therapy, we will proceed to cholangioscopy with SpyGlass ™ DS (Boston Scientific Corporation, USA), treatment of difficult biliary lithiasis with electrohydraulic lithotripsy with Autolith probe (Northgate Technologies Inc USA) and subsequent complete cleaning of the biliary tract using the fluoroscopic technique
Study NCT04889547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intraoperative intravenous dexamethasone
Study NCT04889547 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No dexamethasone
Description: No intraoperative intravenous dexamethasone
Study NCT05974215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of change in bone height by cone beam computed tomography
Description: bone height was measured at 1 ,30 ,90 days after denture insertion
Study NCT06007950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating 10-hr
Description: Time-restricted eating is a form of intermittent fasting. In this study, 10-hr TRE will be employed, where eating duration is limited to 10 hours. Participants are allowed to consume non-caloric beverages during fasting period.
Study NCT06107608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAPI PET/CT
Description: The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is injected intravenously for molecular imaging of FAP expression with FAPI PET/CT.
Study NCT05657717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey
Description: After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
Study NCT04999098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinaforce Forte tablets
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~the tablet contain additional excipients
Study NCT04999098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinaforce Chewable tablets
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~The tablets contain additional excipients
Study NCT04999098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinaforce tincture
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)
Study NCT05624320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584
Description: miotic for treatment of presbyopia
Study NCT05507905 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music associated with dance forms in dance classes.
Study NCT05507905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Classes
Description: Four Different dance forms taught for 6 weeks each
Study NCT05302388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-R002
Description: SIBP-R002: injection; strength: 1, 2, 4, 8 or 12 mg; dose escalation and the first group is 1mg (intravenous infusion, 5 groups, the first group consisted of four people, and the other groups consisted of eight).
Study NCT05302388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone or Methyl prednisolone
Description: Intravenous infusion, 5mg or 1\~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.
Study NCT05302388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone or Methyl prednisolone
Description: Intravenous infusion, 5mg or 1\~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.
Study NCT05302388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.
Study NCT05302388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: 10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.
Study NCT05302388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same volume of placebo as SIBP-R002: injection; strength: the same volume of placebo as SIBP-R002 of 1, 2, 4, 8 or 12 mg (intravenous infusion, 5 groups, the first group consisted of one people, and the other groups consisted of two). The rule and dose of placebo were the same as SIBP-R002.
Study NCT05745831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic decision tool
Description: A therapeutic decision tool will be used and its usefulness, comprehension and satisfaction will be evaluated
Study NCT05039528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized OSA messages
Description: Participants will receive personalized OSA messages designed to nudge and navigate them toward evaluation and treatment for OSA. Participants will complete questionnaires at baseline and at study follow-up.
Study NCT05039528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will complete questionnaires at baseline and at study follow-up. At the end of the study period, participants will receive the OSA message intervention.
Study NCT05323201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fhB7H3.CAR-Ts
Description: fhB7H3.CAR-Ts will be transhepatic arterial infused after lymphodepletion. Three dose levels will be evaluated: Dose Level 1 (1×10\^6/kg), dose Level 2 (3×10\^6/kg) and dose Level 3 (5×10\^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10\^6/kg /infusion) will be evaluated.
Study NCT05323201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3)
Study NCT05323201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 i.v. for once (Day -5)
Study NCT05587439 — intervention group
Intervention type: GENETIC
Intervention: Data and Specimen Collection
Description: * Provide blood and/or saliva sample~* Answer short questionnaires~* Consider consenting to other optional parts of the research such as:~  * use stored tissue samples related to prior cancer treatment~ * Allow access to deceased relatives' medical records and stored specimens~ * Provide blood 1x per year for up to 5 years~ * Provide contact information of family members
Study NCT05117164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enteral feeding as per predefined protocol
Description: Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d.
Study NCT04943367 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TEAS
Description: Transcutaneous electrical acupuncture stimulation
Study NCT04943367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEAS
Description: Transcutaneous electrical acupuncture stimulation
Study NCT05621603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The proposed intervention for the school workforce draws on a mental health integrated disaster preparedness model, emphasizing peer support, developed and used successfully by our team working with communities experiencing multiple disasters.~The 3 hour training is comprised of 4 modules - Module 1: Emergency Preparedness Module 2: Psychological Preparedness Module 3: Peer Support Module 4: Shared Leadership and Feedback Session
Study NCT05788211 — intervention group
Intervention type: OTHER
Intervention: standard of care
Description: retrospective study: standard of care
Study NCT05373459 — intervention group
Intervention type: BIOLOGICAL
Intervention: Third COVID-19 booster
Description: Third COVID-19 booster
Study NCT06421610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PITAC
Description: Cisplatin, oxaliplatin and doxorubicin are standard, commercially available intravenous cytostatic drugs in oncologic treatment with alkylating and topoisomerase inhibitor effect, respectively. Based on the available data and experience from 11 PITAC procedures at OPC, PITAC with cisplatin, oxaliplatin and doxorubicin for intrapleural administration is expected to be well tolerated with a minimal of nausea, subcutaneous emphysema and transient chest pains.
Study NCT05485467 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: coronary CT angiography
Description: Coronary CT angiography will be performed on multislice Siemens Somat Force CT scanner
Study NCT06414694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Oral Challenge
Description: Direct oral challenge to penicillin at a goal dose of 45 mg/kg given in a 10%/90% dose